Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Background: Vascular endothelial growth factor (VEGF)-targeted therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results